title: Prognostic factors to predict outcome following the administration of hypertonic/hyperoncotic solution in hypovolemic patients.
abstract: Hypertonic solutions effectively improve hemodynamic parameters in patients admitted to the emergency room. However, no significant differences in outcome were observed compared with standard isotonic treatment in most previously published studies. This study evaluates pretreatment prognostic factors that predict a beneficial effect of hypertonic solution in patients admitted to the emergency room with hemorrhagic hypovolemia in a prospective double-blind fashion. The patients (n = 212) were randomized upon admission to receive 250 mL intravenous (i.v.) bolus of hypertonic 7.5% NaCl + 6% dextran (HSD, n = 101), or isotonic 0.9% NaCl solutions (IS, n = 111) as the first treatment, followed by standard resuscitation. Pretreatment factors assessed were sex, age, cause of hypovolemia, revised trauma score (RTS), Glasgow index, and mean arterial pressure (MAP) on admission. Both groups were compared for survival at 24 h and 30 days postadmission. Infused volumes were registered. HSD administration significantly increased MAP and reduced i.v. crystalloid infusions to maintain hemodynamic parameters, compared with IS. There was no difference between groups in the number of blood transfusions administered. Overall complication rates in both groups were similar (24%). There was a significant difference (p < .03) in overall (30 days) survival rate between HSD (73%) and IS (64%) groups. The 24 h survival rate was significantly lower in IS (72%) compared with HSD (87%); p < .01. Multivariate analyses showed that RTS and MAP were identified as independent predictors for 24 h survival in the group that received HSD. When evaluated for overall survival rate, hypertonic infusion benefited significantly only patients with MAP < 70 mmHg (p < .01).
authors.affiliation: Department of Surgery, University of São Paulo School of Medicine, Brazil.
authors.forename: R N
authors.initials: RN
authors.lastname: Younes
authors.forename: F
authors.initials: F
authors.lastname: Aun
authors.forename: C T
authors.initials: CT
authors.lastname: Ching
authors.forename: D C
authors.initials: DC
authors.lastname: Goldenberg
authors.forename: M H
authors.initials: MH
authors.lastname: Franco
authors.forename: F K
authors.initials: FK
authors.lastname: Miura
authors.forename: S S
authors.initials: SS
authors.lastname: Santos
authors.forename: I M
authors.initials: IM
authors.lastname: Sequeiros
authors.forename: M
authors.initials: M
authors.lastname: Rocha e Silva
authors.forename: I
authors.initials: I
authors.lastname: Fujimura
authors.forename: D
authors.initials: D
authors.lastname: Birolini
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000627:therapeutic use*; D001794:Blood Pressure; D004311:Double-Blind Method; D004632:Emergency Medical Services; D005260:Female; D006801:Humans; D006982:Hypertonic Solutions / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010952:Plasma Substitutes / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D012769:Shock / Q000628:therapy*
chemical_list: D000418:Albumins; D006982:Hypertonic Solutions; D010952:Plasma Substitutes; C028426:hyperoncotic albumin